Currently, there is at least one approved drug targeting CXCR4: plerixafor (AMD3100). It is primarily used to mobilize hematopoietic stem cells for collection and transplantation in patients with certain types of blood cancers. Although not specifically approved for solid tumors, it represents a proof-of-concept for CXCR4-targeted therapies.
